Journal
PROTEOMICS CLINICAL APPLICATIONS
Volume 7, Issue 1-2, Pages 91-108Publisher
WILEY-V C H VERLAG GMBH
DOI: 10.1002/prca.201200104
Keywords
Biomarker discovery; Experimental autoimmune encephalomyelitis; MS; Multiple sclerosis; Quantitative proteomics
Funding
- Multiple Sclerosis Research Australia (MSRA) Postgraduate Research Scholarship
- Teva Pharmaceuticals
Ask authors/readers for more resources
Multiple sclerosis is an inflammatory-mediated demyelinating disorder most prevalent in young Caucasian adults. The various clinical manifestations of the disease present several challenges in the clinic in terms of diagnosis, monitoring disease progression and response to treatment. Advances in MS-based proteomic technologies have revolutionized the field of biomarker research and paved the way for the identification and validation of disease-specific markers. This review focuses on the novel candidates discovered by the application of quantitative proteomics to relevant disease-affected tissues in both the human context and within the animal model of the disease known as experimental autoimmune encephalomyelitis. The role of targeted MS approaches for biomarker validation studies, such as multiple reaction monitoring will also be discussed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available